The 3-year grant supports the deployment of xRNA Continuous Manufacturing and Process Analytical Technologies to improve RNA therapeutics accessibility in Low- and Middle-Income Countries.
- 3-year grant received from the Bill & Melinda Gates Foundation to enhance RNA production technologies
- Grant enables global implementation of the RNA Continuous Manufacturing platform and advancement of
- Process Analytical Technologies (PAT), developed through an MIT project funded by the FDA
- Focused on improving access to RNA therapeutics in Low- and Middle-Income Countries (LMICs)
ReciBioPharm, a division of Recipharm and a leading Contract Development and Manufacturing Organisation (CDMO), has been awarded a three-year grant from the Bill & Melinda Gates Foundation (Gates Foundation). The funding will support the global deployment of xRNA Continuous Manufacturing technologies to LMICs with a strong focus on the development of state-of-the-art inline PAT capabilities and predictive analytics software. ReciBioPharm’s platform will improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes across the biomanufacturing industry.
Vikas Gupta, President of ReciBioPharm, said: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.”
“Our previously-announced collaboration with MIT has underscored the potential of continuous manufacturing for RNA therapeutics,” added Aaron Cowley, Chief Scientific Officer of ReciBioPharm. “This grant will help to strengthen our role as a pioneer in innovation and support our mission to make lifesaving technologies more accessible.”
This project exemplifies ReciBioPharm’s dedication to addressing global health challenges by combining advanced technologies, scalable processes, and GMP standards to deliver critical RNA-based solutions worldwide.
